JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Eli Lilly and Co.

Cerrado

SectorSanidad

795.48 0.43

Resumen

Variación precio

24h

Actual

Mínimo

785.34

Máximo

798.46

Métricas clave

By Trading Economics

Ingresos

-6.1B

2.8B

Ventas

-804M

13B

P/B

Media del Sector

62.756

50.291

BPA

3.34

Rentabilidad por dividendo

0.79

Margen de beneficios

21.678

Empleados

47,000

EBITDA

-2B

4.2B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+26.16% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.79%

2.40%

Próximas Ganancias

6 ago 2025

Fecha Próximo Dividendo

10 sept 2025

Próxima Fecha de Ex Dividendo

15 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-136B

692B

Apertura anterior

795.05

Cierre anterior

795.48

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

125 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Eli Lilly and Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jun 2025, 11:56 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 may 2025, 14:41 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17 jun 2025, 14:02 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 jun 2025, 12:12 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 jun 2025, 11:01 UTC

Adquisiciones, fusiones, absorciones

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 jun 2025, 10:47 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 jun 2025, 10:47 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 jun 2025, 10:46 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 jun 2025, 10:45 UTC

Adquisiciones, fusiones, absorciones

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 jun 2025, 09:33 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 jun 2025, 09:45 UTC

Charlas de Mercado

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 may 2025, 01:00 UTC

Principales Noticias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New -2-

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 may 2025, 14:02 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 may 2025, 14:01 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 may 2025, 14:00 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 may 2025, 14:00 UTC

Adquisiciones, fusiones, absorciones

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 may 2025, 14:08 UTC

Ganancias

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 18:45 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 may 2025, 17:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 may 2025, 17:01 UTC

Principales Noticias

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 may 2025, 13:56 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 may 2025, 11:18 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 may 2025, 09:30 UTC

Principales Noticias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 may 2025, 20:30 UTC

Principales Noticias

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 may 2025, 04:05 UTC

Adquisiciones, fusiones, absorciones

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 may 2025, 21:07 UTC

Charlas de Mercado

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 may 2025, 14:07 UTC

Ganancias

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Comparación entre iguales

Cambio de precio

Eli Lilly and Co. previsión

Precio Objetivo

By TipRanks

26.16% repunte

Estimación a 12 Meses

Media 999.57 USD  26.16%

Máximo 1,190 USD

Mínimo 700 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Eli Lilly and Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

16

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 884.54Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

125 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.